Eisai's weight-loss drug proves safe, but delivers no heart benefit

Eisai's weight-loss drug Belviq did not increase cardiovascular risk versus placebo, according to results from a long-term Phase 4 clinical trial published Sunday in the New England Journal of Medicine.